GRML (GRML)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GRML (GRML) trades at $0.25 with AI Score 27/100 (Grade F). Greenland Mines Ltd (GRML) is a biotechnology company focused on developing gene therapies for cancer, cardiovascular, and neurodegenerative diseases. Market cap: $18.05M, Sector: Basic materials.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for GRML: GRML does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GRML against Basic Materials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GRML: 1/1 perspectives are bearish.
How is this calculated? →GRML (GRML) Materials & Commodity Exposure
Greenland Mines Ltd, operating in the Other Precious Metals & Mining industry, is a biotechnology firm developing gene therapies, including KLTO-101 for Alzheimer's and KLTO-202 for Lou Gehrig's disease. The company, formerly Klotho Neurosciences, recently rebranded and is based in Omaha, Nebraska, with a small team.
What Is the Investment Thesis for GRML?
Greenland Mines Ltd presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on gene therapy for Alzheimer's and Lou Gehrig's disease addresses significant unmet medical needs. Key value drivers include successful preclinical and clinical trial results for KLTO-101 and KLTO-202. The company's small market capitalization of $18.05M reflects its early stage and inherent risks. A critical risk factor is the company's negative ROE of -198.3% and negative free cash flow of $-0.01 billion, highlighting the need for additional funding. Positive clinical data releases could serve as major catalysts, driving significant stock appreciation. However, the high beta of 2.23 indicates substantial volatility.
Based on FMP financials and quantitative analysis
GRML Key Highlights
- Market capitalization of $18.05M, reflecting its small size and early stage.
- Negative Return on Equity (ROE) of -198.3%, indicating significant losses relative to shareholder equity.
- Negative Free Cash Flow (FCF) of $-0.01 billion, demonstrating the company's reliance on external funding.
- Beta of 2.23, suggesting higher volatility compared to the overall market.
- Focus on gene therapy for Alzheimer's and Lou Gehrig's disease, addressing significant unmet medical needs.
Who Are GRML's Competitors?
GRML is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MTA Metalla Royalty & Streaming Ltd. acquires and manages precious metal royalties and streams, focusing on gold and silver. The company | $7.48 | -2.09% | $698.95M | 68 |
| EMPYF Empress Royalty Corp. | $0.61 | -9.31% | $80.81M | 66 |
| ARIS Aris Mining Corporation | $15.89 | -0.69% | $3.28B | 65 |
| BVN Compañía de Minas Buenaventura S.A.A. is involved in the exploration, mining development, processing, and trading of precious and base metals. The company | $29.86 | +0.49% | $7.59B | 65 |
| MUX McEwen Mining Inc. | $18.89 | -0.08% | $1.13B | 48 |
| WPGCF West Point Gold Corp. | $1.11 | +9.47% | $116.05M | 48 |
| DNRSF Denarius Metals Corp. | $0.45 | +2.04% | $34.28M | 49 |
| NEWP New Pacific Metals Corp. | $4.33 | +1.29% | $797.74M | 49 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GRML's Key Strengths?
- Focus on innovative gene therapy technologies.
- Potential to address unmet medical needs in Alzheimer's and Lou Gehrig's disease.
- Small size allows for agility and flexibility.
- Experienced leadership in biotechnology.
What Are GRML's Weaknesses?
- Limited financial resources.
- Early stage of development with high risk of failure.
- Small team size may limit operational capacity.
- Dependence on successful clinical trial outcomes.
What Could Drive GRML Stock Higher?
- Clinical trial data releases for KLTO-101 in Alzheimer's disease.
- Clinical trial data releases for KLTO-202 in Lou Gehrig's disease.
- Potential strategic partnerships with larger pharmaceutical companies.
- Progress in securing funding for research and development.
What Are the Key Risks for GRML?
- Financial-distress signal — its Altman Z-Score of -0.49 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for KLTO-101 and KLTO-202.
- Regulatory delays or rejection of gene therapy candidates.
- Competition from established pharmaceutical companies.
- Difficulty securing additional funding.
- Intellectual property disputes.
What Are the Growth Opportunities for GRML?
- Successful Clinical Trials: Positive results from clinical trials for KLTO-101 and KLTO-202 would significantly enhance the company's valuation and attract potential partnerships. The Alzheimer's disease therapeutics market is projected to reach billions of dollars, offering substantial revenue potential if KLTO-101 proves effective. Timeline: Ongoing clinical trials with data readouts expected in the next 12-24 months.
- Strategic Partnerships: Collaborating with larger pharmaceutical companies could provide Greenland Mines with access to funding, expertise, and established distribution networks. Strategic alliances can accelerate the development and commercialization of its gene therapy candidates. Timeline: Potential partnership discussions ongoing, with possible agreements within the next 12 months.
- Expansion of Pipeline: Developing additional gene therapy candidates for other neurodegenerative diseases or cancer could diversify the company's portfolio and reduce reliance on KLTO-101 and KLTO-202. This would open up new market opportunities and attract further investment. Timeline: Research and development of new candidates within the next 2-3 years.
- Orphan Drug Designation: Obtaining orphan drug designation for KLTO-101 or KLTO-202 could provide regulatory and financial benefits, including market exclusivity and tax credits. This would incentivize investment and accelerate the development process. Timeline: Application for orphan drug designation within the next 6-12 months.
- Acquisition Target: Given its focus on innovative gene therapies, Greenland Mines could become an attractive acquisition target for larger pharmaceutical companies seeking to expand their pipelines. An acquisition would provide shareholders with a significant return on investment. Timeline: Potential acquisition within the next 3-5 years, contingent on clinical trial progress.
What Opportunities Does GRML Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of pipeline to other disease areas.
- Orphan drug designation for KLTO-101 and KLTO-202.
- Acquisition by a larger pharmaceutical company.
What Threats Does GRML Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Difficulty securing funding.
What Are GRML's Competitive Advantages?
- Proprietary gene therapy technologies.
- Intellectual property protection through patents.
- First-mover advantage in specific disease areas.
- Expertise in gene therapy research and development.
What Does GRML Do?
Greenland Mines Ltd, formerly known as Klotho Neurosciences, was founded with the goal of developing innovative gene therapies for challenging diseases. The company rebranded in March 2026, signaling a strategic shift in its corporate identity. Based in Omaha, Nebraska, Greenland Mines focuses on creating medicines for cancer, cardiovascular, and neurodegenerative disorders. Its primary focus is on gene therapy product candidates, including KLTO-101, which targets the treatment or prevention of Alzheimer's disease, and KLTO-202, a gene therapy product designed for the treatment and prevention of Lou Gehrig's disease (ALS). The company is still in the early stages of development and research. Greenland Mines operates with a small team, emphasizing a lean approach to biotechnology research and development. The company's success hinges on the clinical trial outcomes and regulatory approvals for its gene therapy candidates.
What Products and Services Does GRML Offer?
- Develops gene therapies for cancer.
- Develops gene therapies for cardiovascular disorders.
- Develops gene therapies for neurodegenerative disorders.
- Focuses on KLTO-101 for Alzheimer's disease treatment or prevention.
- Focuses on KLTO-202 for Lou Gehrig's disease (ALS) treatment or prevention.
- Conducts research and development activities.
- Seeks regulatory approvals for its gene therapy candidates.
How Does GRML Make Money?
- Develops and patents gene therapy technologies.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its therapies.
- Seeks partnerships with larger pharmaceutical companies for funding and commercialization.
- Aims to generate revenue through licensing agreements or product sales upon regulatory approval.
What Industry Does GRML Operate In?
Greenland Mines Ltd operates within the highly competitive and rapidly evolving biotechnology industry. The gene therapy market is projected to experience substantial growth, driven by technological advancements and increasing prevalence of genetic disorders. Competition includes established pharmaceutical companies and specialized biotech firms also developing gene therapies for neurological diseases. Success in this market requires significant investment in research and development, navigating complex regulatory pathways, and securing intellectual property rights. The industry is characterized by high risk and potential for high reward, with clinical trial outcomes heavily influencing company valuations.
Who Are GRML's Key Customers?
- Future patients suffering from cancer, cardiovascular, and neurodegenerative disorders.
- Healthcare providers who will administer the gene therapies.
- Pharmaceutical companies that may license or acquire Greenland Mines' technologies.
- Research institutions involved in clinical trials.
Company Profile
GRML operates in the Other Precious Metals industry within the Basic Materials sector. It is headquartered in Omaha, US. The company is led by CEO Joseph A. Sinkule. GRML has traded publicly since 2022.
How GRML Is Valued
GRML carries a market capitalization of $18.05M, placing it in the micro-cap category. Relative to its peer group, GRML's quantitative score of 27/100 is below the peer average of 62/100.
Key Financial Metrics
Return on assets is -37.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -52.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.74 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -92.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
GRML's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.49 places it in the distress zone, a signal of elevated financial risk.
GRML Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recientemente, se ha observado un aumento en la actividad de compra por parte de los insiders, lo que sugiere confianza en el futuro de la empresa.
- El sentimiento de la comunidad ha sido mayormente positivo, con discusiones que destacan innovaciones y desarrollos recientes.
- Los analistas han elogiado la estrategia de crecimiento de la empresa, lo que ha generado un ambiente optimista entre los inversores.
- Las redes sociales han reflejado un creciente interés en la marca, lo que podría traducirse en un aumento de la demanda.
Bear Case
- A pesar del optimismo, algunos inversores expresan preocupaciones sobre la sostenibilidad del crecimiento a largo plazo de la empresa.
- Se han reportado críticas sobre la falta de claridad en la comunicación de la dirección, lo que ha generado desconfianza entre algunos accionistas.
- El aumento en la competencia en su sector ha llevado a dudas sobre la capacidad de la empresa para mantener su cuota de mercado.
- El sentimiento general del mercado ha sido volátil, lo que podría afectar negativamente la percepción de los inversores sobre el futuro de GRML.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GRML Latest News
-
9 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Jun 24, 2026
GRML Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRML.
Price Targets
Wall Street price target analysis for GRML.
GRML MoonshotScore
What does this score mean?
The MoonshotScore rates GRML's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Joseph A. Sinkule
CEO
Joseph A. Sinkule is the CEO of Greenland Mines Ltd, managing a small team of three employees. His background includes experience in the pharmaceutical and biotechnology industries. He has held various leadership positions in research and development, focusing on drug discovery and clinical development. Sinkule has a strong understanding of the regulatory landscape and the challenges of bringing new therapies to market. His expertise lies in strategic planning, business development, and team leadership.
Track Record: Since becoming CEO of Greenland Mines Ltd, Joseph A. Sinkule has focused on advancing the company's gene therapy programs for Alzheimer's and Lou Gehrig's disease. He has overseen the rebranding of the company from Klotho Neurosciences to Greenland Mines Ltd. His leadership is geared towards securing funding, advancing clinical trials, and establishing strategic partnerships to drive the company's growth.
GRML Basic Materials Stock FAQ
What does GRML do?
Greenland Mines Ltd is a biotechnology company focused on developing gene therapies for the treatment of cancer, cardiovascular, and neurodegenerative disorders. The company's lead product candidates, KLTO-101 and KLTO-202, target Alzheimer's disease and Lou Gehrig's disease (ALS), respectively. GRML aims to address significant unmet medical needs by developing innovative gene therapies that can potentially modify the course of these debilitating diseases. The company is currently in the early stages of clinical development, with a focus on advancing its lead candidates through clinical trials and securing regulatory approvals.
What do analysts say about GRML stock?
As of March 16, 2026, there is no readily available analyst coverage for Greenland Mines Ltd (GRML). This is likely due to the company's small market capitalization ($0.03 billion) and early stage of development. Investors should conduct their own due diligence and consider the inherent risks associated with investing in a small-cap biotechnology company. Key valuation metrics to consider include the potential market size for its gene therapy candidates, the probability of success in clinical trials, and the company's ability to secure funding. The stock's high beta of 2.23 suggests it is more volatile than the overall market.
What are the main risks for GRML?
Greenland Mines Ltd faces several significant risks typical of small-cap biotechnology companies. The primary risk is the potential failure of its clinical trials for KLTO-101 and KLTO-202. Clinical trial failures can result in a significant loss of investment. The company also faces regulatory risks, including potential delays or rejection of its gene therapy candidates by regulatory agencies. Competition from established pharmaceutical companies with greater resources is another risk. Finally, GRML faces ongoing financial risks, including the need to secure additional funding to support its research and development activities. The company's negative ROE and free cash flow highlight its reliance on external funding.
What are the key factors to evaluate for GRML?
GRML holds an AI score of 27/100 (low). Not financial advice.
How frequently does GRML data refresh on this page?
GRML prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GRML's recent stock price performance?
GRML moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative gene therapy technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GRML overvalued or undervalued right now?
Valuing GRML requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GRML?
Before investing in GRML, research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Greenland Mines Ltd due to its small size and early stage of development.
- AI analysis pending, which may provide additional insights.